The global hemophilia treatment market size was US$ 12.8 billion in 2021. The global hemophilia treatment market size is forecast to reach US$ 26.9 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.5% during the forecast period from 2022 to 2030.
Hemophilia is a term used to describe a set of bleeding diseases in which blood clots slowly. Hemophilia is of two types: hemophilia A and hemophilia B. In addition, the cause of hemophilia is the deficiency of clotting factor VIII or IX in the blood. Bleeding is the most common symptom of hemophilia. The main treatment is to inject a clotting factor into a vein to replace the missing clotting factor in the blood (intravenous infusions). As a result, the surgeon operating on the patient must be aware of the disease. It's also critical to share information about the ailment with blood relatives, as they may afflict it as well.
Factors Influencing Market Growth
Impact Analysis of COVID-19
The COVID-19 pandemic had a negative impact on the global market. Patients with such illnesses had a higher risk of contracting coronavirus because they were more susceptible to infectious infections. Several organizations, hospitals, and hematologists, on the other hand, were working hard to manage the COVID-19 public health pandemic.
Regional Analysis
Europe garnered the major market share in 2021 and is forecast to remain dominant during the forecast period. Due to the well-established healthcare structures, current technical advances, and rising demand for early diagnosis of hemophilia owing to increasing awareness regarding the disease.
The Asia Pacific region is forecast to have lucrative growth during the forecast period. As a result of the growing incidence of the population suffering from hemophilia. In addition, rising healthcare expenditure drives market growth in the region.
Leading Competitors
The leading prominent companies profiled in the global hemophilia treatment market are:
Scope of the Report
The global hemophilia treatment market segmentation focuses on Type, Drug Therapy, and Region.
Segmentation based on Type
Segmentation based on Drug Therapy
Segmentation based on Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL HEMOPHILIA TREATMENT MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
4 GLOBAL HEMOPHILIA TREATMENT MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS
5 GLOBAL HEMOPHILIA TREATMENT MARKET, BY TYPE
5.1 OVERVIEW
5.2 HEMOPHILIA A
5.3 HEMOPHILIA B
6 GLOBAL HEMOPHILIA TREATMENT MARKET, BY DRUG THERAPY
6.1 OVERVIEW
6.2 RECOMBINANT COAGULATION FACTOR CONCENTRATES THERAPY
6.3 PLASMA-DERIVED COAGULATION FACTOR CONCENTRATES THERAPY
6.4 NON-FACTOR REPLACEMENT THERAPY
6.5 OTHERS
7 GLOBAL HEMOPHILIA TREATMENT MARKET, BY GEOGRAPHY
7.1 OVERVIEW
7.2 NORTH AMERICA
7.2.1 NORTH AMERICA MARKET SNAPSHOT
7.2.2 U.S.
7.2.3 CANADA
7.2.4 MEXICO
7.3 EUROPE
7.3.1 EUROPE MARKET SNAPSHOT
7.3.2 WESTERN EUROPE
7.3.2.1 THE UK
7.3.2.2 GERMANY
7.3.2.3 FRANCE
7.3.2.4 ITALY
7.3.2.5 SPAIN
7.3.2.6 REST OF WESTERN EUROPE
7.3.3 EASTERN EUROPE
7.3.3.1 POLAND
7.3.3.2 RUSSIA
7.3.3.3 REST OF EASTERN EUROPE
7.4 ASIA PACIFIC
7.4.1 ASIA PACIFIC MARKET SNAPSHOT
7.4.2 CHINA
7.4.3 JAPAN
7.4.4 INDIA
7.4.5 AUSTRALIA & NEW ZEALAND
7.4.6 ASEAN
7.4.7 REST OF ASIA PACIFIC
7.5 MIDDLE EAST & AFRICA
7.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
7.5.2 UAE
7.5.3 SAUDI ARABIA
7.5.4 SOUTH AFRICA
7.5.5 REST OF MEA
7.6 SOUTH AMERICA
7.6.1 SOUTH AMERICA MARKET SNAPSHOT
7.6.2 BRAZIL
7.6.3 ARGENTINA
7.6.4 REST OF SOUTH AMERICA
8 GLOBAL HEMOPHILIA TREATMENT MARKET COMPETITIVE LANDSCAPE
8.1 OVERVIEW
8.2 COMPANY MARKET RANKING
8.3 KEY DEVELOPMENT STRATEGIES
9 COMPANY PROFILES
9.1 BAYER AG
9.1.1 OVERVIEW
9.1.2 FINANCIAL PERFORMANCE
9.1.3 PRODUCT OUTLOOK
9.1.4 KEY DEVELOPMENTS
9.2 CSL LTD. (CSL BEHRING)
9.2.1 OVERVIEW
9.2.2 FINANCIAL PERFORMANCE
9.2.3 PRODUCT OUTLOOK
9.2.4 KEY DEVELOPMENTS
9.3 F. HOFFMANN-LA ROCHE AG
9.3.1 OVERVIEW
9.3.2 FINANCIAL PERFORMANCE
9.3.3 PRODUCT OUTLOOK
9.3.4 KEY DEVELOPMENTS
9.4 GRIFOLS, S.A.
9.4.1 OVERVIEW
9.4.2 FINANCIAL PERFORMANCE
9.4.3 PRODUCT OUTLOOK
9.4.4 KEY DEVELOPMENTS
9.5 MEDEXUS PHARMACEUTICALS INCORPORATED
9.5.1 OVERVIEW
9.5.2 FINANCIAL PERFORMANCE
9.5.3 PRODUCT OUTLOOK
9.5.4 KEY DEVELOPMENTS
9.6 NOVO NORDISK A/S
9.6.1 OVERVIEW
9.6.2 FINANCIAL PERFORMANCE
9.6.3 PRODUCT OUTLOOK
9.6.4 KEY DEVELOPMENTS
9.7 OCTAPHARMA AG
9.7.1 OVERVIEW
9.7.2 FINANCIAL PERFORMANCE
9.7.3 PRODUCT OUTLOOK
9.7.4 KEY DEVELOPMENTS
9.8 PFIZER INCORPORATED
9.8.1 OVERVIEW
9.8.2 FINANCIAL PERFORMANCE
9.8.3 PRODUCT OUTLOOK
9.8.4 KEY DEVELOPMENTS
9.9 SWEDISH ORPHAN BIOVITRUM AB
9.9.1 OVERVIEW
9.9.2 FINANCIAL PERFORMANCE
9.9.3 PRODUCT OUTLOOK
9.9.4 KEY DEVELOPMENTS
9.10 TAKEDA PHARMACEUTICALS COMPANY LIMITED
9.10.1 OVERVIEW
9.10.2 FINANCIAL PERFORMANCE
9.10.3 PRODUCT OUTLOOK
9.10.4 KEY DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved